|
|
||||||||
1 Respiratory Research Unit, and 2 Biochemical Analysis Dept, Hospital Nuestra Señora de Candelaria, Tenerife, Spain. 3 Pulmonary and Critical Care Division, St. Elizabeth's Medical Center, Boston, MA, USA.
CORRESPONDENCE: J. P. de Torres, Unidad de Investigación, Hospital Nuestra Señora de Candelaria, Ctra del Rosario s/n, 38010 Santa Cruz de Tenerife, Canary Islands, Spain. Fax: 34 922600562. E-mail: jupa65{at}hotmail.com
Keywords: Chronic obstructive pulmonary disease, C-reactive protein, systemic inflammation
Received: September 19, 2005
Accepted January 3, 2006
The aim of this study was to determine the relationship between C-reactive protein (CRP) levels and factors known to predict outcome in stable chronic obstructive pulmonary disease (COPD) patients.
The following were studied in 130 stable COPD patients: spirometry, lung volume, arterial oxygen tension (Pa,O2), dyspnoea, 6-min walk distance (6MWD), body mass index, fat-free mass index, BODE (body mass index, obstruction, dyspnoea and exercise capacity), health-related quality of life, smoking status, the presence of cardiovascular risk factors or disease, corticosteroid use and number of exacerbations in the previous year. CRP levels were measured in these patients and in 65 controls. Using univariate and multivariate analyses, any possible association with the predictors of outcomes was evaluated.
CRP levels were higher in COPD patients than in controls (4.1 versus 1.8 mg·L1, respectively). Correlation was found with the following variables: forced expiratory volume in one second (FEV1; 0.23), FEV1 % (0.20), forced vital capacity (FVC; 0.24), FVC % (0.24), Global Initiative for Chronic Obstructive Lung Disease stage (0.17), BODE (0.17), inspiratory capacity/total lung capacity (0.20), Pa,O2 (0.40) and 6MWD (0.30). Using multivariate analysis, Pa,O2 and 6MWD manifested the strongest negative association with CRP levels.
C-reactive protein levels in stable chronic obstructive pulmonary disease patients are best correlated with arterial oxygen tension and 6-min walk distance. This should be considered when C-reactive protein levels are measured in stable chronic obstructive pulmonary disease patients.
This article has been cited by other articles:
![]() |
J B Morjaria, A J Chauhan, K S Babu, R Polosa, D E Davies, and S T Holgate The role of a soluble TNF{alpha} receptor fusion protein (etanercept) in corticosteroid refractory asthma: a double blind, randomised, placebo controlled trial Thorax, July 1, 2008; 63(7): 584 - 591. [Abstract] [Full Text] [PDF] |
||||
![]() |
D. D. Sin and S. F. P. Man Biomarkers in COPD: Are We There Yet? Chest, June 1, 2008; 133(6): 1296 - 1298. [Full Text] [PDF] |
||||
![]() |
J. P. de Torres, V. Pinto-Plata, C. Casanova, H. Mullerova, E. Cordoba-Lanus, M. Muros de Fuentes, A. Aguirre-Jaime, and B. R. Celli C-Reactive Protein Levels and Survival in Patients With Moderate to Very Severe COPD Chest, June 1, 2008; 133(6): 1336 - 1343. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. A. Falk, O. A. Minai, and Z. Mosenifar Inhaled and Systemic Corticosteroids in Chronic Obstructive Pulmonary Disease Proceedings of the ATS, May 1, 2008; 5(4): 506 - 512. [Abstract] [Full Text] [PDF] |
||||
![]() |
H. Watz, B. Waschki, C. Boehme, M. Claussen, T. Meyer, and H. Magnussen Extrapulmonary Effects of Chronic Obstructive Pulmonary Disease on Physical Activity: A Cross-sectional Study Am. J. Respir. Crit. Care Med., April 1, 2008; 177(7): 743 - 751. [Abstract] [Full Text] [PDF] |
||||
![]() |
N L Mills, J J Miller, A Anand, S D Robinson, G A Frazer, D Anderson, L Breen, I B Wilkinson, C M McEniery, K Donaldson, et al. Increased arterial stiffness in patients with chronic obstructive pulmonary disease: a mechanism for increased cardiovascular risk Thorax, April 1, 2008; 63(4): 306 - 311. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. K. Han, V. V. McLaughlin, G. J. Criner, and F. J. Martinez Pulmonary Diseases and the Heart Circulation, December 18, 2007; 116(25): 2992 - 3005. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. J Hancox, R. Poulton, J. M Greene, S. Filsell, C. R McLachlan, F. Rasmussen, D R. Taylor, M. J A Williams, A. Williamson, and M. R Sears Systemic inflammation and lung function in young adults Thorax, December 1, 2007; 62(12): 1064 - 1068. [Abstract] [Full Text] [PDF] |
||||
![]() |
R A Stockley Biomarkers in COPD: time for a deep breath Thorax, August 1, 2007; 62(8): 657 - 660. [Full Text] [PDF] |
||||
![]() |
R. Tkacova and P. Joppa Angiotensin-converting enzyme genotype and C-reactive protein in patients with COPD Eur. Respir. J., April 1, 2007; 29(4): 816 - 817. [Full Text] [PDF] |
||||
![]() |
M. N. Hylkema, P. J. Sterk, W. I. de Boer, and D. S. Postma Tobacco use in relation to COPD and asthma Eur. Respir. J., March 1, 2007; 29(3): 438 - 445. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. M. Hoeper, T. Welte, R. Tkacova, and P. Joppa Systemic Inflammation, COPD, and Pulmonary Hypertension Chest, February 1, 2007; 131(2): 634 - 635. [Full Text] [PDF] |
||||
![]() |
G. C. Donaldson C-reactive Protein: Does It Predict Mortality? Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 209 - 210. [Full Text] [PDF] |
||||
![]() |
M. Dahl, J. Vestbo, P. Lange, S. E. Bojesen, A. Tybjaerg-Hansen, and B. G. Nordestgaard C-reactive Protein As a Predictor of Prognosis in Chronic Obstructive Pulmonary Disease Am. J. Respir. Crit. Care Med., February 1, 2007; 175(3): 250 - 255. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. P. Hersh, D. T. Miller, D. J. Kwiatkowski, and E. K. Silverman Genetic determinants of C-reactive protein in COPD Eur. Respir. J., December 1, 2006; 28(6): 1156 - 1162. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. P. Anderson COPD, asthma and C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 874 - 876. [Full Text] [PDF] |
||||
![]() |
E. F. M. Wouters The systemic face of airway diseases: the role of C-reactive protein. Eur. Respir. J., May 1, 2006; 27(5): 877 - 879. [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |